Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating DMX-200 repagermanium, a drug that blocks a receptor involved in inflammation, in patients with focal segmental glomerulosclerosis FSGS who are also receiving an angiotensin II receptor blocker ARB. This Phase 3 study aims to assess the safety and effectiveness of DMX-200 compared to placebo over two years in adults and adolescents aged 12 to 17 years. The study is led by Dimerix Bioscience Pty Ltd and includes a double-blind period followed by an open-label extension to observe long-term effects. Participants receive either 120 mg of DMX-200 or a matching placebo capsule twice daily for 104 weeks during the double-blind treatment phase. Afterward, those who complete this phase may enter a two-year open-label extension where all participants receive DMX-200 twice daily. The study includes a screening and qualification period lasting 6 to 14 weeks, a possible titration phase, a stabilization phase, and a follow-up period after treatments. Throughout the trial, patients will undergo assessments including urine proteincreatinine ratio and kidney function tests like estimated glomerular filtration rate eGFR at multiple time points up to week 104 and during the extension. Safety and tolerability are closely monitored through regular evaluations, adverse event tracking, and follow-up visits. Total participation may last about 230 weeks, covering all study phases and follow-up periods.
Actively Recruiting
Researchers are evaluating povetacicept for its efficacy, safety, and tolerability in people with primary membranous nephropathy pMN, a kidney condition. This Phase 2b3 adaptive, randomized study compares povetacicept with the calcineurin inhibitor tacrolimus to determine which treatment better supports clinical remission of pMN. Participants will be randomly assigned to receive one of two doses of povetacicept, given as a subcutaneous injection, or tacrolimus capsules taken orally. The study includes sequential phases, with dosing based on previous phase results. Participants will receive their assigned treatment and be monitored throughout the study. During participation, individuals will be assessed for clinical remission at 104 weeks, and safety will be monitored up to 112 weeks by tracking adverse events. Researchers will conduct regular evaluations to measure how well the treatments work and their tolerability. The total study duration extends up to nearly four years, with ongoing monitoring and data collection.
Actively Recruiting
Researchers are evaluating the use of oral ivosidenib in adults with locally advanced or metastatic conventional chondrosarcoma that has an IDH1 gene mutation. This Phase 3, international, multicenter, double-blind study compares ivosidenib to a placebo in participants who have measurable disease that has progressed or recurred and who have received up to two prior systemic treatments. The trial focuses on progression-free survival as the primary outcome, especially in Grades 1 and 2 chondrosarcoma participants. Participants will be randomly assigned to receive either ivosidenib 500 mg tablets or matching placebo tablets taken orally once daily. Treatment continues until disease progression confirmed by a blinded independent central review, unacceptable side effects, pregnancy, death, withdrawal, loss to follow-up, or study end. Those on placebo who experience disease progression and meet criteria may cross over to receive ivosidenib. The estimated average treatment duration is about two years. During the study, participants will undergo regular imaging scans to assess tumor response and progression according to RECIST criteria. Researchers will monitor survival outcomes up to five years and evaluate safety through adverse event reporting. Quality of life questionnaires and blood tests to measure drug and biomarker levels will be collected. The total participation duration may extend up to five years, including treatment and follow-up assessments.
Actively Recruiting
Researchers are investigating whether adding preoperative chemotherapy to surgery improves the outcomes for patients with high risk retroperitoneal sarcoma, specifically dedifferentiated liposarcoma DDLPS and leiomyosarcoma LMS. This phase III randomized trial compares the effects of surgery alone versus surgery following chemotherapy on disease-free survival in these patients. Participants are assigned to one of two groups the standard treatment group, which undergoes large en-bloc curative-intent surgery within four weeks after randomization, or the experimental group, which receives three cycles of chemotherapy before surgery. Chemotherapy regimens differ by sarcoma type, with high grade LPS patients receiving doxorubicin plus ifosfamide every three weeks, and LMS patients receiving doxorubicin plus dacarbazine every three weeks. Surgery is then scheduled 3 to 6 weeks after the last chemotherapy cycle, with doses adapted per institutional guidelines. During the study, participants undergo imaging assessments to evaluate tumor operability and response to treatment. Researchers monitor disease-free survival over seven years from the first patient enrolled, along with secondary outcomes including overall survival, recurrence, metastasis rates, treatment safety, quality of life, and pathological response. Participants are closely followed through scheduled visits and tests to assess treatment effects and potential complications until study completion in 2028.